Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated With Immune‐Checkpoint Inhibitors

Oncologist - United States
doi 10.1634/theoncologist.2018-0563

Related search